News

Latest news

Hide mandatory notifications of trade

Solon Eiendom - Primary insider notification regarding subscription rights in the subsequent offering

SOLON EIENDOM ASA

STOCK EXCHANGE ANNOUNCEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SWITZERLAND OR THE UNITED STATES

Solon Eiendom - Primary insider notification regarding subscription rights in the subsequent offering

(Oslo, Norway, 13 January 2017) Reference is made to the stock exchange announcement on 12 January 2017 by Solon Eiendom ASA ("Solon" or the "Company", ticker "SOLON") regarding inter alia the subsequent offering of 666,666,666 new shares in the Company at a subscription price of NOK 0.15 per share (the "Subsequent Offering") to shareholders of the Company as per the end of 23 November 2016 (as registered in the Norwegian Central Securities Depository (the "VPS") as per the end of 25 November 2016 , the "Record Date") who shall have preferential rights to subscribe for new shares in the Company, provided such shareholders are (i) not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action, (ii) and/or who were not allocated shares in the private placement announced on 24 November 2016 (the "Private Placement"), (iii) and/or who did not participate in the guarantee consortium for the Private Placement (the "Eligible Shareholders").

Eligible Shareholders will receive 0.65129 subscription rights ("Subscription Rights") for each share held as per the Record Date. Subscription Rights will not be awarded based on the shares subscribed for in the Private Placement or for shares issued as transaction consideration to the sellers of shares in Solon Eiendom AS.

Certain primary insiders of the Company have received Subscription Rights in the Subsequent Offering. The following table sets out details in respect of such primary insiders:

Name Position  Shareholding as at
the Record Date 
Subscription Rights  Total shareholding
(if all Subscription Rights
are exercised) 
Unni Hjelmaas
through Hjelmaas AS

 CEO
in Bionor Pharma AS (*)

 473,476  308,370  781,846
Gunnar Flåten

 VP Director of Finance
in Bionor Pharma AS (*)

 1,617,500  1,053,461  2,670,961
 Maja Sommerfelt SVP Chief Scientific Officer
in Bionor Pharma AS (*)
 910,393  592,929  1,503,322
 Cecilie Grue
through Grue Invest AS
Director of Legal Affairs  301,099  196,102  497,201

(*) Bionor Pharma AS (previously Bionor Immuno AS) is a wholly owned subsidiary of Solon Eiendom ASA.


Further information
Simen Thorsen
Chairman of the Board, Solon Eiendom ASA
E-mail: st@soloneiendom.no
Cell Phone: +47 918 86 886

Andreas Martinussen
Chief Executive Officer, Solon Eiendom ASA
E-mail: am@soloneiendom.no
Cell Phone: +47 400 00 405

About Solon Eiendom
Solon Eiendom is a Norwegian residential real estate development company focusing on the Oslo and Akershus region. Solon Eiendom was established in 2006 by founder Simen Thorsen and investor Tore Aksel Voldberg. The company has since its incorporation delivered 570 units with a corresponding sales value of close to NOK ~3 billion and sold more than 800 units with a total sales price of more than NOK ~4 billion.

About Bionor
Bionor Pharma's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine Vacc-4x in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor currently retains full ownership rights to the HIV immunotherapy Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company's shareholders. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.

Important Information
The release is not for publication or distribution, in whole or in part directly or  indirectly,  in  or  into  Australia,  Canada,  Japan, Hong Kong  or  the United States (including  its territories and possessions, any  state of the United States and the  District  of  Columbia).

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States.  Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan, Hong Kong or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor SpareBank 1 Markets AS assumes any responsibility in the event there is a violation by any person of such restrictions.The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.